泰国儿童狂犬病暴露前预防2剂与3剂方案随机对照试验
该研究在泰国2-12岁健康儿童中比较2剂与3剂狂犬病暴露前预防方案的免疫原性。2剂组78人、3剂组29人,初免后所有受试者中和抗体均≥0.5 IU/ml;1年后2剂组仅80%维持该水平,但加强后两组均100%达标,支持儿童采用2剂方案。
要点
- 2剂组初免后中和抗体GMT为18.6 IU/ml,3剂组为16.3 IU/ml,差异无统计学意义。
- 初免1年后2剂组仅80%儿童抗体≥0.5 IU/ml,3剂组为100%。
- 加强后7天两组抗体均100%达标,支持儿童2剂暴露前预防。
核心结论
- 2剂基础狂犬病免疫在初免后和加强后均提供足够抗体,支持儿童采用2剂暴露前预防方案。
研究设计与样本
- 随机开放标签试验,纳入107名2-12岁健康泰国儿童,随机分为2剂组78人和3剂组29人。
- 2剂组第0、28天接种,3剂组第0、7、28天接种,均肌肉注射纯化Vero细胞狂犬病疫苗。
主要发现
- 初免完成后所有受试者中和抗体均≥0.5 IU/ml,GMT 2剂组18.6(95%CI 15.9-21.8)、3剂组16.3(95%CI 13.2-20.1)IU/ml,P=0.35。
- 初免1年后加强前,2剂组80%儿童中和抗体≥0.5 IU/ml,3剂组100%,P=0.01。
- 加强后7天两组所有受试者中和抗体均≥0.5 IU/ml,GMT 2剂组20.9(95%CI 17.4-25.3)、3剂组22.2(95%CI 15.8-31.4)IU/ml,P=0.75。
- 加强后7天干扰素-γ分泌细胞中位数2剂组98、3剂组128 SFCs/10^6 PBMCs,P=0.30。
关键数值与推荐
- 中和抗体滴度≥0.5 IU/ml视为抗体充足。
临床怎么用
- 儿童暴露前狂犬病预防可考虑2剂方案(第0、28天),初免后抗体达标且加强后免疫应答良好。
局限性
- 2剂组与3剂组样本量不均衡(78比29),可能影响组间比较的把握度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: World Health Organization changed the recommendation for pre-exposure rabies prophylaxis from 3-dose to 2-dose regimen in 2018. Given limited data of 2-dose regimens in pediatric population, this study aimed to compare the immunogenicity between 2-dose and 3-dose pre-exposure rabies immunization. METHODS: This study was conducted among healthy children aged 2-12 years. They were randomized to 2-dose vaccination (2D) on days 0 and 28 or 3-dose vaccination (3D) on days 0, 7, and 28. Purified Vero cell rabies vaccine (PVRV-Verorab™) was administered intramuscularly. Rabies virus neutralizing antibody (RVNA) titers were measured at 3 time points: 14-day after complete vaccination, 1-year pre-booster vaccination, and 7-day post-booster dose to mimic scenario of rabies exposure. RVNA titers ≥0.5 IU/ml were considered adequate antibody. T cell specific response to rabies vaccine antigen was measured using the interferon-gamma enzyme linked immunospot assay. RESULTS: From September to October 2017, 107 participants (51% males), 78 in 2D group and 29 in 3D group were enrolled. Median age was 5.8 years (IQR 4.4-7.3). All participants had RVNA titers ≥0.5 IU/ml after primary vaccination [GMT 2D: 18.6 (95%CI 15.9-21.8) and 3D: 16.3 (95%CI 13.2-20.1 IU/ml), p = 0.35]. At 1-year prior to receiving the booster, only 80% of the children in 2D group maintained RVNA titers ≥0.5 IU/ml compared to 100% of the children in 3D group (p = 0.01). However, all participants in both groups had RVNA ≥0.5 IU/ml at 7-day post booster vaccination [GMT 2D: 20.9 (95%CI 17.4-25.3) and 3D: 22.2 (95%CI 15.8-31.4) IU/ml (P = 0.75)]. The median number of IFN-γ secreting cells at 7-day post-booster dose was 98 and 128 SFCs per 106 PBMCs in the 2D and 3D groups, respectively (P = 0.30). CONCLUSIONS: Two-dose primary rabies immunization provided adequate antibody at post primary vaccination and post booster. The results support 2-dose regimen of pre-exposure rabies immunization in the pediatric population.
引用
- Janewongwirot P, Jantarabenjakul W, Anugulruengkitt S, et al. A randomized open-label trial of 2-dose or 3-dose pre-exposure rabies prophylaxis among Thai children. Vaccine. 2019. PMID: 31358408. doi:10.1016/j.vaccine.2019.07.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。